Casdin Capital increased its position in clinical-stage biotech firm Relay Therapeutics (RLAY) by 11.21% during the second quarter of 2026, according to a recent SEC 13F filing. The filing, which reflects holdings as of June 30, 2026, shows the investor's stake grew from 14.42 million to 16.04 million shares. This disclosure provides a delayed look at portfolio changes and doesn't represent a single-day trade.
The investment firm's reported value in RLAY more than doubled to $300.02 million, also making it a more significant part of their portfolio at 15.02%. This move came before recent news in late August of analyst downgrades and a significant cut to the company's 2026 revenue outlook, which caused the stock to slide. Prior to that, in mid-August, some analysts had raised their price targets for the company.